Close

Visiongain predicts boom in pharma contract manufacturing market

Related stories

New Syngene biologics manufacturing facility to be operational for US and European customers from mid-year

At DCAT 2024 global bio/pharmaceutical manufacturing forum, Syngene International,...

ST Pharm breaks ground on 2nd oligonucleotide manufacturing plant

ST Pharm said it has taken its first step...

Elevating Biopharmaceutical Projects With The Right CDMO

In the biopharma industry, selecting the right contract development...

Biovian announces over €50 million investment in manufacturing facility in Turku, Finland

Biovian, a leading contract development and manufacturing organization (CDMO)...

New PAT – Based Strategy Stops Membrane Fouling In SP – TFF

A recent article published in the Journal of Membrane...

The global contract manufacturing will reach $64.07bn in 2016, according to a new report by London-based business information company Visiongain. The report, ‘Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021,’ says that the market will grow with a CAGR of 8.7% between 2010 and 2016, with finished dosage forms manufacturing driving the revenue growth. API manufacturing remained the largest market sector in 2010, accounting for 71.1% of the total market and the API manufacturers in India and China will achieve increasing demand for their services.Between 2011 and 2021, demand for contract manufacturing services will continue to come from developed market-based pharmaceutical companies, the Visiongain report says.

This decade, pharmaceutical companies will outsource increasing amounts of manufacturing, as companies focus on activities such as R&D and marketing. Growth in the biotechnology market will also provide a great opportunity for contract manufacturing organisations.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories